InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
T+90 hit rate
60%
T+90 mean return
-4.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Shetzline Michael, CMO, SVP & Responsable du Développement Médical. Officer active across 1 company, notably Ironwood Pharmaceuticals INC. Cumulatively, 19 filings have been published. Breakdown: 0 buy · 10 sells. Total volume traded: €1.2m. History available since 24 May 2021. The latest transaction was filed on 10 February 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations19 total
133,333 shares0Class A Common StockSEC:0000950170-25-019235:0
48,224 shares0Class A Common StockSEC:0000950170-25-007852:0
16,128 shares@ US$6.458.1% of flowClass A Common StockSEC:0000950170-24-063481:0
34,936 shares0Class A Common StockSEC:0000950170-24-029906:0
38,618 shares@ US$15.2445.9% of flowClass A Common StockSEC:0000950170-24-015557:0
57,971 shares0Class A Common StockSEC:0001209191-24-001905:0
10,324 shares@ US$10.128.1% of flowClass A Common StockSEC:0001209191-23-031874:0
69,869 shares0Class A Common StockSEC:0001209191-23-017889:0
7,146 shares@ US$11.416.5% of flowClass A Common StockSEC:0001209191-23-014280:0
14,663 shares0Class A Common StockSEC:0001209191-23-003999:0
3,130 shares@ US$11.500.0057% mcap9.1% of flowClass A Common StockSEC:0001209191-22-031842:0
81,448 shares0Class A Common StockSEC:0001209191-22-016184:0
1,367 shares@ US$10.770.0022% mcap3.5% of flowClass A Common StockSEC:0001209191-22-014652:0
29,326 shares0Class A Common StockSEC:0001104659-22-006551
29,326 shares0Class A Common StockSEC:0001104659-22-006551:0
13,776 shares@ US$11.580.024% mcap38.1% of flowClass A Common StockSEC:0001209191-21-066780:0
13,776 shares@ US$11.5812.0% of flowClass A Common StockSEC:0001209191-21-066780
2,077 shares@ US$12.250.0035% mcap5.6% of flowClass A Common StockSEC:0001209191-21-035905:0
2,077 shares@ US$12.255.6% of flowClass A Common StockSEC:0001209191-21-035905
19 of 19 declarations
About Shetzline Michael
Michael Shetzline is the CMO, Senior Vice President, and Head of Drug Development at Ironwood Pharmaceuticals Inc. He oversees drug development initiatives, focusing on innovation and efficiency. His expertise in the pharmaceutical field is crucial for the success of the company's research and development projects.
